Austin Bigley Email

VP Research . Indapta Therapeutics

Seattle & Houston,

Location

a*****@indapta.com

Primary Email

LinkedIn

Current Roles

Employees:
29
Revenue:
$4.5M
About
Indapta's allogeneic g-NK cells have highly potent ADCC activity, making them the ideal therapy to combine with IgG1 monoclonal antibodies, ADCs, or innate immune cell engager molecules.
Indapta Therapeutics Address

Seattle & Houston, null
United States
Indapta Therapeutics Email

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.